Endometriosis Pipeline Review, H2 2018: Analysis of 24 Companies & Drug Profiles - ResearchAndMarkets.com

September 24, 2018

DUBLIN--(BUSINESS WIRE)--Sep 24, 2018--The “Endometriosis - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Endometriosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Endometriosis (Women’s Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women’s Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 10, 15, 2, 12, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 3 molecules, respectively.

Endometriosis (Women’s Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Endometriosis - Overview Endometriosis - Therapeutics Development Endometriosis - Therapeutics Assessment Endometriosis - Companies Involved in Therapeutics Development Endometriosis - Drug Profiles Endometriosis - Dormant Projects Endometriosis - Discontinued Products Endometriosis - Product Development Milestones Appendix

Companies Mentioned

Addex Therapeutics Ltd Auritec Pharmaceuticals Inc Bayer AG Chugai Pharmaceutical Co Ltd Daewoong Pharmaceutical Co Ltd ElexoPharm GmbH EndoCeutics Inc Enteris BioPharma Inc Evotec AG Forendo Pharma Ltd GeneScience Pharmaceuticals Co Ltd Immunitor Inc Jiangsu Hengrui Medicine Co Ltd Kissei Pharmaceutical Co Ltd Luye Pharma Group Ltd Nippon Shinyaku Co Ltd Ogeda SA Philogen SpA Predictive Therapeutics LLC Repros Therapeutics Inc SK Chemicals Co Ltd Takeda Pharmaceutical Co Ltd ValiRx Plc Viramal Ltd For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mvfb9c/endometriosis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005344/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Women’s Health,Sexual and Reproductive Health Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/24/2018 04:23 AM/DISC: 09/24/2018 04:23 AM


Update hourly